Australia appears to be gain access to innovative therapy for obesity: Retatrutide. This dual compound – targeting on both GLP-1 and GIP receptors – demonstrates significant outcomes in global studies, indicating meaningful reductions in weight. While regulatory clearance is pending with the Therapeutic Goods Administration (TGA), several peopl